ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.245 USD 0.78%
Market Cap: 402m USD

During the last 3 months ADC Therapeutics SA insiders bought 15m USD , and have not sold any shares. The stock price has dropped by 2% over this period (open performance analysis).

The last transaction was made on Oct 27, 2025 by Redmile Group, Llc , who bought 15m USD worth of ADCT shares.

Last Transactions:
Redmile Group, Llc
$+15m
Redmile Group, Llc
$+54m
Redmile Group, Llc
$+114k
Redmile Group, Llc
$-52.5k
Redmile Group, Llc
$+1.1m
Azelby Robert
$-20.2k
Bizzari Jean-Pierre
$-20.2k
Hug Peter
$-3.4k
Monges Viviane
$-4.2k
Pfisterer Thomas
$-4.2k
Sandor Victor
$-20.2k
Squarer Ron
$-20.2k
Redmile Group, Llc
$+29.4m
Mallik Ameet
$-133.2k
View All Transactions

During the last 3 months ADC Therapeutics SA insiders bought 15m USD , and have not sold any shares. The stock price has dropped by 2% over this period (open performance analysis).

The last transaction was made on Oct 27, 2025 by Redmile Group, Llc , who bought 15m USD worth of ADCT shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
1
15m USD
3-6
months
1
54m USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
1
114k USD

ADC Therapeutics SA
Insider Trading Chart

ADC Therapeutics SA
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

ADC Therapeutics SA
Last Insider Transactions

Global
Insiders Monitor

ADC Therapeutics SA
Glance View

Market Cap
365.5m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.542 USD
Undervaluation 29%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top